IVERIC bio, Inc. Common Stock
ISEE
ISEE was delisted on the 10th of July, 2023.
191 hedge funds and large institutions have $1.58B invested in IVERIC bio, Inc. Common Stock in 2016 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 73 increasing their positions, 61 reducing their positions, and 22 closing their positions.
45% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 22
20% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 61
5% more funds holding
Funds holding: 182 → 191 (+9)
2% less call options, than puts
Call options by funds: $49.8M | Put options by funds: $50.7M
8% less capital invested
Capital invested by funds: $1.71B → $1.58B (-$134M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$44.3M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$28.5M |
| 3 |
TBC
Three Bays Capital
Boston,
Massachusetts
|
+$27.9M |
| 4 |
Goldman Sachs
New York
|
+$26.2M |
| 5 |
EA
Emerald Acquisition
Seattle,
Washington
|
+$16.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$55.4M |
| 2 |
Morgan Stanley
New York
|
-$27M |
| 3 |
Millennium Management
New York
|
-$24.8M |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$22.1M |
| 5 |
SPC
Slate Path Capital
New York
|
-$21.9M |
ISEE Hedge Fund Activity: Q3 2016 in Review
191 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in IVERIC bio, Inc. Common Stock (ISEE) for Q3 2016, worth a combined $1.58B — down 7.9% from $1.71B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new ISEE positions and 22 closed out — a net gain of 10 holders — while 73 added to existing stakes and 61 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $44.3M. The largest seller was OrbiMed, cutting an estimated $55.4M.
- 191 institutional investors held IVERIC bio, Inc. Common Stock (ISEE) as of Q3 2016, up from 182 in Q2 2016.
- Funds reported $1.58B of IVERIC bio, Inc. Common Stock stock for Q3 2016, down 7.9% quarter-over-quarter.
- 32 funds opened new IVERIC bio, Inc. Common Stock positions in Q3 2016 and 22 closed out, a net change of +10 holders.
- The largest IVERIC bio, Inc. Common Stock buyer in Q3 2016 was Point72 Asset Management, an estimated $44.3M added.
- The largest IVERIC bio, Inc. Common Stock seller in Q3 2016 was OrbiMed, an estimated $55.4M sold.
Based on aggregated 13F filings for Q3 2016.